Regulatory crosstalk between TGF-β signaling and miRNAs: a head and neck cancer perspective
Pragati Karemore,Jayasree Peroth Jayaprakash,Kumar Pranav Narayan,Piyush Khandelia
DOI: https://doi.org/10.1007/s13237-024-00499-x
2024-07-14
Nucleus
Abstract:Cancers originating from mucosal epithelium in the oral cavity, pharynx, larynx, and paranasal sinuses give rise to aggressive, heterogeneous, genetically complex, challenging to treat head and neck squamous cell carcinoma (HNSCC). HNSCC is frequently associated with tobacco consumption, alcohol abuse, and other risk factors like viral infections such as Epstein-Barr Virus (EBV) and Human Papillomavirus (HPV). Many therapies, including surgery, neoadjuvant, chemotherapy, radiotherapy, and combinational therapies, have been applied to treat HNSCC. Despite this, the survival rate of HNSCC patients has not increased by > 5 years in the last three decades. A plethora of cellular signaling pathways, including transforming growth factor beta (TGF-β) signaling, impacts HNSCC pathophysiology and progression. TGF-β is a pleiotropic secreted cytokine that plays an indispensable role in the development and progression of HNSCC via its paradoxical regulatory function in both early and later stages. Defective TGF-β signaling often contributes to HNSCC pathophysiology and pathogenesis. MicroRNAs are small non-coding RNAs regulating mammalian gene expression post-transcriptionally, and their crosstalk with cellular signaling pathways is well documented. TGF-β-induced miRNAs are involved in the pathophysiology of different types of cancers, including HNSCC. TGF-β and miRNA correlation are very often used for the classification, diagnosis, and prognosis of cancers, including HNSCC. Here, we review the current literature on the mutual regulatory roles of miRNAs and TGF-β signaling pathways in HNSCC pathophysiology and their potential for developing meaningful, targeted therapies.
cell biology